Yann Joly, Ph.D. (DCL), is a Lawyer and an Assistant Professor at the Faculty of Medicine, Department of Human Genetics at McGill University, as well as an ethics and legal consultant in the private sector. He is the North American coordinator of the Association de recherche et de formation en droit medical (ARFDM) and the Data Access Officer of the International Cancer Genome Consortium (ICGC). His research activities lie at the interface of the fields of intellectual property, health law (biotechnology and other emerging health technologies) and bioethics. In recent years, Yann Joly has worked as a lecturer teaching intellectual property and biotechnology law at both McGill University and the Université de Montreal law faculties. He has served as a legal advisor on several ethics committees of the MUHC and is currently a member of the Independent Ethics Advisory Committee for the biotechnology company Genizon Biosciences.

Yann Joly is a co-author of the recent report from the Canadian Academy of Health Sciences on the topic of the returns on investments in health research. He has authored more than 50 articles on the legal issues raised by the development, integration and use of new health technologies in leading legal and scientific journals.